CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults
Open Access
- 9 July 2013
- journal article
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 9 (1) , 24
Abstract
Atopic dermatitis (AD) is a condition frequently encountered in medical practices across the country. Arming ourselves with appropriate and safe treatment modalities to provide relief for this chronic and relapsing inflammatory condition is of utmost importance to our patients and their families. Utilizing topical calcineurin inhibitors (TCIs) for the treatment of AD not responsive to high-potency corticosteroids, or low-potency corticosteroids and localized to the face, eyelids, and skin folds of patients >2 years, is reasonable to include in common practice. Despite the FDA’s Black Box warning, to date no evidence has been published linking the TCIs to an increased incidence of malignancy in either children or adults that establishes causation. The Canadian Society of Allergy and Clinical Immunology (CSACI) therefore recognizes that the benefits of TCIs should be carefully weighed with the theoretical risks in advising patients, and acknowledges that long-term studies remain in progress. The safety and efficacy of topical tacrolimus and pimecrolimus should therefore be considered when treating children and adults with AD in Canadian allergy and immunology practices.Keywords
This publication has 18 references indexed in Scilit:
- Comparative Effectiveness of Topical Calcineurin Inhibitors in Adult Patients with Atopic DermatitisAmerican Journal of Clinical Dermatology, 2012
- Atopic dermatitisAllergy, Asthma & Clinical Immunology, 2011
- Atopic DermatitisAnnals of Dermatology, 2010
- Topical Treatments with Pimecrolimus, Tacrolimus and Medium- to High-Potency Corticosteroids, and Risk of LymphomaDermatology, 2009
- The prevalence of atopic triad in children with physician-confirmed atopic dermatitisJournal of the American Academy of Dermatology, 2008
- Risk of Lymphoma Following Exposure to Calcineurin Inhibitors and Topical Steroids in Patients with Atopic DermatitisJournal of Investigative Dermatology, 2007
- Consensus Statement on the Safety Profile of Topical Calcineurin InhibitorsDermatology, 2005
- Atopic DermatitisNew England Journal of Medicine, 2005
- Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and ImmunologyJournal of Allergy and Clinical Immunology, 2005
- Disease management of atopic dermatitis: an updated practice parameterAnnals of Allergy, Asthma & Immunology, 2004